//
P.Nombela Blanco
R.Lozano Mejorada
D.Lorente Estelles
A.Reid
N.Romero Laorden
G.Attard
Y.Cendn Flrez
J.Mateo
S.Sandhu
C.Massard
A.Montesa
P.Flohr
M.I.Sez
M.I.Pacheco
E.Castro Marcos
J.de Bono
D.Olmos Hidalgo
Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Pediatric Oncology, Hospital Universitari i Politecnic La Fe, Valencia, Spain
Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, UK
Genomics Unit, CNIO- Spanish National Cancer Center, Madrid, Spain
Drug Development Unit, The Institute of Cancer Research & Royal Marsden, Sutton, UK
Dept. of Hematology, Peter MacCallum Cancer Center, Melbourne, Australia
Early Drug Development Department, Institut de Gustave Roussy, Villejuif, France
CNIO-IBIMA Genitorurinary Cancer Clinical Research Unit, Hospitales Universitarios Virgen de la Victoria & Regional de Malaga, Malaga, Spain
Medical Oncology, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga, Spain
Section of Medicine, Institute of Cancer Research Royal Marsden Hospital, Sutton, UK
Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Spain
United Kingdom
Australia
France
N/A
Oncology (ONC)
Nephrology
N/A
Circulating tumor cells
Prostate specific antigen
Docetaxel
N/A
Multicenteric
Prospective
Cohort
NA
N/A
N/A
N/A